A newly launched UK biotech is looking to develop a new approach to immunotherapy, based around a seemingly paradoxical idea that stimulating cancer makes them more visible to the body’s de
The departure of its head of research and the unblinding of a cancer drug trial wrongfooted Bayer late last week, just as the firm wanted to trumpet its broad pipeline.
